Keratin 19 expression correlates with poor prognosis in breast cancer

Molecular Biology Reports

Volumn 41, Issue 12, 2014, Pages 7729-7735

  Kabir, Nuzhat N ^a   Rönnstrand, Lars ^b   Kazi, Julhash U ^a,b  

^a KN Biomedical Research Institute   (Bangladesh)

^b LUND UNIVERSITY   (Sweden)

Author keywords

CK19; Cytokeratin 19; KRT19; Microarray

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TUMOR PROTEIN; TUMOR PROTEIN D52; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-19; PROGNOSIS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84926635773     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3684-6     Document Type: Article

References (19)

1. Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32(5):617–628. doi:10.1038/emboj.2013.19
2. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96(16):9212–9217
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093
4. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4(5):348–353
5. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362(9381):362–369. doi:10.1016/S0140-6736(03)14023-8
6. Kabir NN, Rönnstrand L, Kazi JU (2013) The basic helix-loop-helix (bHLH) proteins in breast cancer progression. Med Oncol 30(3):666. doi:10.1007/s12032-013-0666-9
7. Kabir NN, Rönnstrand L, Kazi JU (2013) Deregulation of protein phosphatase expression in acute myeloid leukemia. Med Oncol 30(2):517. doi:10.1007/s12032-013-0517-8
8. Kabir NN, Rönnstrand L, Kazi JU (2013) Protein kinase C expression is deregulated in chronic lymphocytic leukemia. Leuk Lymphoma 54(10):2288–2290. doi:10.3109/10428194.2013.769220
9. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA, Hirsch EF, Kavanah M, Mendez J, Stone M, Gerry NP, Lenburg ME, Rosenberg CL (2008) Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer (Journal international du cancer) 122(7):1557–1566. doi:10.1002/ijc.23267
10. Pau Ni IB, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Aina Emran N, Hisham Abdullah N, Syed Hussain SN (2010) Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. Pathol Res Pract 206(4):223–228. doi:10.1016/j.prp.2009.11.006
11. Emery LA, Tripathi A, King C, Kavanah M, Mendez J, Stone MD, de las Morenas A, Sebastiani P, Rosenberg CL (2009) Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol 175(3):1292–1302. doi:10.2353/ajpath.2009.090115
12. Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13(4):1033–1067. doi:10.1677/ERC-06-0001
13. Boutros R, Fanayan S, Shehata M, Byrne JA (2004) The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun 325(4):1115–1121. doi:10.1016/j.bbrc.2004.10.112
14. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG (2005) Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65(24):11259–11264. doi:10.1158/0008-5472.CAN-05-2495
15. Coulombe PA, Omary MB (2002) ‘Hard’ and ‘soft’ principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 14(1):110–122
16. Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40(5):403–439
17. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53(1):61–66
18. Zhang DH, Tai LK, Wong LL, Sethi SK, Koay ES (2005) Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 5(7):1797–1805. doi:10.1002/pmic.200401069
19. Kabir NN, Kazi JU (2011) Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity. Genet Mol Biol 34(4):587–591. doi:10.1590/S1415-47572011005000035